10 August 2026
The tumor suppressor p53 plays a central role in cellular stress responses and the maintenance of cellular homeostasis. While TP53 mutations occur in approximately half of all cancers, many TP53 wild-type tumors circumvent p53-mediated tumor suppressor function through overexpression or amplification of the negative regulator MDM2. Consequently, the MDM2-p53 interaction has emerged as a major focus of cancer research and therapeutic development.
To support the scientific community in exploring p53 biology and MDM2-driven pathways, Boehringer Ingelheim is making BI-7828 available through opnMe. BI-7828 entered Phase III clinical evaluation and has been extensively characterized in pharmacological, translational, and clinical studies. Although further clinical development was discontinued following the Phase III Brightline-1 study, BI-7828 remains a valuable tool for mechanistic and translational research. Importantly, the molecule is supported by a rich translational data package, including evidence of p53 pathway activation and biomarker responses such as GDF15 induction.
BI-7828 is a highly potent small-molecule antagonist of the MDM2-p53 protein-protein interaction. By binding to the p53-binding pocket of MDM2, it prevents MDM2-mediated suppression of p53 and restores p53 pathway signaling. The molecule combines single-digit nanomolar potency with strong cellular activity, oral bioavailability, favorable pharmacokinetics, and durable antitumor activity in preclinical models.
Researchers can use BI-7828 to investigate p53 pathway activation, MDM2 biology, and the consequences of p53 reactivation in relevant disease models. To support rigorous experimental design, BI-7828 is complemented by the matched negative control BI-8965.
Access the full BI-7828 profile on opnMe and order both the active molecule and its matched negative control free of charge to support your research.
No registration required
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About BI-7828:
BI-7828 is a potent small-molecule antagonist of the MDM2-p53 protein-protein interaction. By binding to the p53-binding pocket of MDM2, it prevents MDM2-mediated suppression of p53 in TP53 wild-type cells and model systems. BI-7828 combines single-digit nanomolar biochemical potency with robust cellular activity, oral bioavailability, and extensive pharmacological characterization. These properties make it a valuable tool for both in vitro and in vivo research. A structurally related negative control compound, BI-8965, is also available to support mechanistic studies. The related spiro-oxindole derivative BI-0282 has also been made available on opnMe.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. As part of our “Molecules to Order” pillar, we share well-characterized tool compounds free of charge with no IP strings attached. With “opn2EXPERTS”, we enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our opn2TALENTS PostDoc grants provide an opportunity for high-caliber talents to pitch their scientific approaches for well-defined research questions to conduct their research at one of our discovery research sites.